サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1529671

爪白癬の市場規模、シェア、動向分析レポート：タイプ別、治療別、地域別、セグメント予測、2024年～2030年

Onychomycosis Market Size, Share & Trends Analysis Report By Type (Distal Subungual, White Superficial, Proximal Subungual Onychomycosis), By Treatment (Oral, Topical), By Region, And Segment Forecasts, 2024 - 2030

出版日
ページ情報
英文 140 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
爪白癬の市場規模、シェア、動向分析レポート：タイプ別、治療別、地域別、セグメント予測、2024年～2030年
出版日: 2024年07月05日
発行: Grand View Research
ページ情報: 英文 140 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

爪白癬市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の爪白癬市場規模は2030年に49億4,000万米ドルと推定され、2024年から2030年にかけてCAGR 4.4%で成長する見込みです。

爪白癬市場の成長は、治療に対する意識の高まりに助けられた爪白癬と慢性疾患の発生率の増加に起因しています。感染症は心理的・社会的制限につながり、仕事や社会生活を制限する可能性があるため、感染症に苦しむ患者に効果的かつ効率的な治療を提供することが重要になり、市場の成長をさらに促進しています。

爪白癬の増加率は、市場全体の成長に寄与する主な要因です。この感染症は、しばしば爪白癬または真菌性爪感染症として知られ、米国では全人口の14％以上が罹患しています。しかし、爪白癬は性質上非常に伝染しやすく、加齢とともに発症リスクが高まるにもかかわらず、ほとんどの人は爪白癬がどれほど有害であるかを知らないです。

Global Nail Fungus Organizationのような国際的な組織は、世界中の公衆衛生関係者やヘルスケア専門家と協力して、世界中で爪真菌に対する認識を高め、予防と治療の改善に努めています。このことは、治療薬の需要を促進すると予想されます。米国疾病予防管理センター（CDC）による「Think Fungus（真菌について考えよう）」などの政府のイニシアチブは、爪白癬などの真菌性疾患を患者の経過の早い段階で発見し、適切な治療を確実に行うことの重要性を強調しています。このため、爪白癬治療薬に対する需要が急増しており、同国の市場成長を牽引すると期待されています。

さらに、主なプレーヤーは、新規の爪白癬治療薬を開発し、市場での競争力を維持するために、共同研究やパートナーシップに注力しています。例えば、2022年8月、Moberg Pharma ABはPadagis Israel Agencies Ltd.と販売契約を締結し、イスラエルにおける爪水虫治療薬MOB-015の独占販売権をPadagisに与える見込みです。さらに、患者のコンプライアンス向上や投与量の削減といった懸念事項に対処するための技術革新が、市場の成長を促進すると予想されています。例えば、インタス・ファーマシューティカルズは2021年10月、世界初のスーパー・バイオアベイラブル・イトラコナゾールであるSB 100mgをItaspor-SB Forte/Subawinのブランド名で発売しました。この取り組みにより、患者のコンプライアンスが大幅に向上し、治療費が削減されることが期待されます。

爪白癬市場レポートハイライト

  • 遠位爪下爪白癬セグメントが2022年の市場を独占しており、これは有病率の増加と、高まる需要に対応するためのFDAによるジェネリック承認数に起因しています。
  • 外用剤セグメントは、患者の治療コンプライアンス向上につながる使用と投与の容易さにより、予測期間中に最も速い成長率を示すと予想されます。
  • 競合各社は、競争上の優位性を維持・発展させるため、資本集約的な専門設備の獲得に注力するようになっています。
  • 北米は2022年に最大の市場シェアを占めたが、これはヘルスケアへのアクセスの良さ、幅広い対象人口の存在、治療の高い普及率に起因しています。

目次

第1章 調査手法と範囲

第2章 爪白癬市場：エグゼクティブサマリー

  • 市場スナップショット
  • タイプスナップショット
  • 治療スナップショット
  • 競合情勢のスナップショット

第3章 爪白癬市場の変数、動向、範囲

  • 市場セグメンテーションと範囲
  • 市場系統の見通し
    • 親市場の見通し
    • 関連/補助市場見通し
  • 市場力学
  • 市場促進要因分析
    • 爪白癬の発生率増加
    • 爪白癬の治療に関する意識の高まり
    • 高齢者と糖尿病患者の増加
  • 市場抑制要因分析
    • 高齢者と糖尿病患者の増加
  • 爪白癬市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTLE分析
    • 価格分析
    • パイプライン分析

第4章 爪白癬市場：タイプ別 推定・動向分析

  • 世界の爪白癬市場：タイプ別セグメントダッシュボード
  • 世界の爪白癬市場：タイプ変動分析
  • 世界の爪白癬市場規模と動向分析、タイプ別、2018～2030年
  • 遠位爪甲下爪真菌症
  • 表在性白色爪真菌症
  • 近位爪甲下爪真菌症
  • その他のタイプ

第5章 爪白癬市場：治療別推定・動向分析

  • 世界の爪白癬市場：治療セグメントダッシュボード
  • 世界の爪白癬市場：治療変動分析
  • 世界の爪白癬市場規模と動向分析、治療別、2018～2030年
  • 経口
  • 外用
  • その他

第6章 地域別ビジネス分析

  • 地域別市場ダッシュボード
  • 世界の地域別市場スナップショット
  • 市場規模、予測動向分析、2018年から2030年：
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • スペイン
    • フランス
    • イタリア
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • 韓国
    • タイ
    • オーストラリア
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 企業/競合の分類
  • 参入企業概要
  • 財務実績
  • 製品外用
  • 企業の市場シェア分析
  • 戦略マッピング、2023年
    • Bausch Health Companies Inc.
    • GSK plc.
    • Abbott
    • Pfizer, Inc.
    • Bayer AG
    • Teva Pharmaceutical Industries Ltd.
    • Cipla Inc.
    • Merck & Co., Inc.
    • Novartis AG
    • Sun Pharmaceutical Industries Ltd.
    • Moberg Pharma AB
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviation
  • Table 3 Incidence of Diseases
  • Table 4 Global Onychomycosis Market, By Region, 2018 - 2030 (USD Million)
  • Table 5 North America Onychomycosis Market, By Country, 2018 - 2030 (USD Million)
  • Table 6 North America Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 7 North America Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 8 U.S. Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 9 U.S. Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 10 Canada Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 11 Canada Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 12 Europe Onychomycosis Market, By Country, 2018 - 2030 (USD Million)
  • Table 13 Europe Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 14 Europe Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 15 Germany Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 16 Germany Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 17 UK Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 18 UK Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 19 France Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 20 France Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 21 Italy Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 22 Italy Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 23 Spain Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 24 Spain Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 25 Denmark Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 26 Denmark Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 27 Sweden Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 28 Sweden Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 29 Norway Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 30 Norway Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 31 Asia Pacific Onychomycosis Market, By Country, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific Onychomycosis Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 34 Japan Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 35 Japan Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 36 China Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 37 China Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 38 India Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 39 India Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 40 South Korea Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 41 South Korea Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 42 Australia Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 43 Australia Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 44 Thailand Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 45 Thailand Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 46 Latin America Onychomycosis Market, By Country, 2018 - 2030 (USD Million)
  • Table 47 Latin America Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 48 Latin America Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 49 Brazil Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 50 Brazil Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 51 Mexico Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 52 Mexico Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 53 Argentina Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 54 Argentina Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 55 Middle East & Africa Onychomycosis Market, By Country, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 59 Saudi Arabia Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 60 South Africa Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 61 South Africa Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 62 UAE Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 63 UAE Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 64 Kuwait Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 65 Kuwait Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Onychomycosis Market Segmentation
  • Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 11 Penetration & Growth Prospect Mapping
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Market Penetration & Growth Prospect Mapping
  • Fig. 15 Onychomycosis market: Type outlook and key takeaways
  • Fig. 16 Onychomycosis market: Type movement analysis & market share 2023 & 2030
  • Fig. 17 Distal subungual onychomycosis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 White superficial onychomycosis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Proximal subungual onychomycosis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Onychomycosis market: Treatment outlook and key takeaways
  • Fig. 22 Onychomycosis market: Treatment movement analysis & market share 2023 & 2030
  • Fig. 23 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Topical market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Regional Marketplace: Key Takeaways
  • Fig. 27 Regional Outlook, 2023 & 2030
  • Fig. 28 Regional Market Dashboard
  • Fig. 29 Regional Market: Key Takeaways
  • Fig. 30 North America Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 31 U.S. Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Canada Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Europe Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 34 UK Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Germany Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 36 France Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Italy Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Spain Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Denmark Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Sweden Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Norway Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Asia-Pacific Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Japan Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 44 China Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 45 India Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 46 Australia Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Thailand Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 48 South Korea Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 49 Latin America Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Brazil Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Mexico Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 52 Argentina Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 53 MEA Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 54 South Africa Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 55 Saudi Arabia Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 56 UAE Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 57 Kuwait Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 58 Strategy Mapping
目次
Product Code: GVR-4-68040-031-4

Onychomycosis Market Growth & Trends:

The global onychomycosis market size was estimated at USD 4.94 Billion in 2030 and is expected to grow at a CAGR of 4.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growth of the onychomycosis market is attributable to the increasing incidence of onychomycosis and chronic diseases aided by rising awareness about treatment. The infection leads to psychological and social limitations which can limit an individual's ability to work and socialize which makes it important to provide effective and efficient treatment for patients suffering from the infection further propelling the market growth.

Rising rate of onychomycosis is the key factor contributing to the overall growth of the market. The infection, often known as toenail fungus or fungal nail infection, affects over 14% of the total population in the U.S. However, most people are unaware of how harmful toenail fungus is, despite it is extremely contagious in nature and increasing the risk of developing with age.

International organizations such as the Global Nail Fungus Organization are working with public health officials and healthcare professionals worldwide to increase awareness and improve the prevention and treatment of nail fungus across the globe. This is anticipated to propel the demand for therapeutics. Government initiatives such as Think Fungus by the Centers for Disease Control and Prevention (CDC), emphasize the significance of detecting fungal diseases such as onychomycosis, early enough in the course of a patient's condition to ensure the administration of relevant therapy. This is inducing a surge in demand for onychomycosis therapeutics and is expected to drive market growth in the country.

Furthermore, the key players are focusing on collaborations and partnerships to develop novel onychomycosis therapies and to maintain their competitive position in the market. For instance, in August 2022, Moberg Pharma AB entered into a distribution agreement with Padagis Israel Agencies Ltd. that is expected to give Padagis exclusive rights for selling and marketing MOB-015, a treatment for onychomycosis in Israel. Moreover, innovations to address the concerns such as improving patient compliance and reducing the dosage are expected to fuel the market growth. For instance, in October 2021, Intas Pharmaceuticals launched SB 100mg under the brand name Itaspor-SB Forte/Subawin which is the world's first Super Bioavailable Itraconazole. This initiative is expected to significantly increase patient compliance and reduce the cost of therapy.

Onychomycosis Market Report Highlights:

  • Distal subungual onychomycosis segment dominated the market in 2022 and is attributable to the increasing prevalence and number of generic approvals by the FDA to meet the rising demands
  • Topical segment is expected to show the fastest growth rate over the forecast period owing to ease of usage and administration which leads to increased patient compliance with treatment
  • Players have an increased focus on acquiring specialized capacities that are highly capital-intensive to develop and maintain their competitive position
  • North America held the largest market share in 2022 which can be attributed to better access to healthcare, the presence of a wide target population, and high adoption of treatment

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Type Segment
      • 1.1.1.2. Treatment Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information Or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Primary Sources
  • 1.11. List of Abbreviations

Chapter 2. Onychomycosis Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Type Snapshot
  • 2.3. Treatment Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Onychomycosis Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Increasing Incidence of Onychomycosis
    • 3.4.2. Rising Awareness About Treatment of Onychomycosis
    • 3.4.3. Rising Awareness About Treatment of Onychomycosis
    • 3.4.4. Growing Geriatric and Diabetic Populations
  • 3.5. Market Restraint Analysis
    • 3.5.1. Growing Geriatric and Diabetic Populations
  • 3.6. Onychomycosis Market Analysis Tools
    • 3.6.1. Industry Analysis - Porter's
      • 3.6.1.1. Supplier Power
      • 3.6.1.2. Buyer Power
      • 3.6.1.3. Substitution Threat
      • 3.6.1.4. Threat of New Entrant
      • 3.6.1.5. Competitive Rivalry
    • 3.6.2. PESTLE Analysis
      • 3.6.2.1. Political Landscape
      • 3.6.2.2. Technological Landscape
      • 3.6.2.3. Economic Landscape
    • 3.6.3. Pricing Analysis
    • 3.6.4. Pipeline Analysis

Chapter 4. Onychomycosis Market: Type Estimates & Trend Analysis

  • 4.1. Global Onychomycosis Market: Type Segment Dashboard
  • 4.2. Global Onychomycosis Market: Type Movement Analysis
  • 4.3. Global Onychomycosis Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. Distal Subungual Onychomycosis
    • 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.5. White Superficial Onychomycosis
    • 4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.6. Proximal Subungual Onychomycosis
    • 4.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.7. Other Types
    • 4.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. Onychomycosis Market: Treatment Estimates & Trend Analysis

  • 5.1. Global Onychomycosis Market: Treatment Segment Dashboard
  • 5.2. Global Onychomycosis Market: Treatment Movement Analysis
  • 5.3. Global Onychomycosis Market Size & Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
  • 5.4. Oral
    • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.5. Topical
    • 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. Regional Business Analysis

  • 6.1. Regional Market Dashboard
  • 6.2. Global Regional Market Snapshot
  • 6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. U.S.
      • 6.4.1.1. Key Country Dynamics
      • 6.4.1.2. Competitive Scenario
      • 6.4.1.3. Regulatory Framework/Reimbursement Framework
      • 6.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Canada
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Competitive Scenario
      • 6.4.2.3. Regulatory Framework/Reimbursement Framework
      • 6.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. UK
      • 6.5.1.1. Key Country Dynamics
      • 6.5.1.2. Competitive Scenario
      • 6.5.1.3. Regulatory Framework/Reimbursement Framework
      • 6.5.1.4. UK Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Germany
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Competitive Scenario
      • 6.5.2.3. Regulatory Framework/Reimbursement Framework
      • 6.5.2.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.3. Spain
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Competitive Scenario
      • 6.5.3.3. Regulatory Framework/Reimbursement Framework
      • 6.5.3.4. Spain Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Competitive Scenario
      • 6.5.4.3. Regulatory Framework/Reimbursement Framework
      • 6.5.4.4. France Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Competitive Scenario
      • 6.5.5.3. Regulatory Framework/Reimbursement Framework
      • 6.5.5.4. Italy Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.6. Denmark
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Competitive Scenario
      • 6.5.6.3. Regulatory Framework/Reimbursement Framework
      • 6.5.6.4. Denmark Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.7. Sweden
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Competitive Scenario
      • 6.5.7.3. Regulatory Framework/Reimbursement Framework
      • 6.5.7.4. Sweden Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.8. Norway
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Competitive Scenario
      • 6.5.8.3. Regulatory Framework/Reimbursement Framework
      • 6.5.8.4. Norway Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Japan
      • 6.6.1.1. Key Country Dynamics
      • 6.6.1.2. Competitive Scenario
      • 6.6.1.3. Regulatory Framework/Reimbursement Framework
      • 6.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.2. China
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Competitive Scenario
      • 6.6.2.3. Regulatory Framework/Reimbursement Framework
      • 6.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.3. India
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Competitive Scenario
      • 6.6.3.3. Regulatory Framework/Reimbursement Framework
      • 6.6.3.4. India Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.4. South Korea
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Competitive Scenario
      • 6.6.4.3. Regulatory Framework/Reimbursement Framework
      • 6.6.4.4. South Korea Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.5. Thailand
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Competitive Scenario
      • 6.6.5.3. Regulatory Framework/Reimbursement Framework
      • 6.6.5.4. Thailand Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Australia
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Competitive Scenario
      • 6.6.6.3. Regulatory Framework/Reimbursement Framework
      • 6.6.6.4. Australia Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Brazil
      • 6.7.1.1. Key Country Dynamics
      • 6.7.1.2. Competitive Scenario
      • 6.7.1.3. Regulatory Framework/Reimbursement Framework
      • 6.7.1.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.7.2. Mexico
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Competitive Scenario
      • 6.7.2.3. Regulatory Framework/Reimbursement Framework
      • 6.7.2.4. Mexico Onychomycosis Market, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Competitive Scenario
      • 6.7.3.3. Regulatory Framework/Reimbursement Framework
      • 6.7.3.4. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.8. MEA
    • 6.8.1. South Africa
      • 6.8.1.1. Key Country Dynamics
      • 6.8.1.2. Competitive Scenario
      • 6.8.1.3. Regulatory Framework/Reimbursement Framework
      • 6.8.1.4. South Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.8.2. Saudi Arabia
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Competitive Scenario
      • 6.8.2.3. Regulatory Framework/Reimbursement Framework
      • 6.8.2.4. Saudi Arabia Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.8.3. UAE
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Competitive Scenario
      • 6.8.3.3. Regulatory Framework/Reimbursement Framework
      • 6.8.3.4. UAE Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.8.4. Kuwait
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Competitive Scenario
      • 6.8.4.3. Regulatory Framework/Reimbursement Framework
      • 6.8.4.4. Kuwait Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company /Competition Categorization
  • 7.2. Participant Overview
  • 7.3. Financial Performance
  • 7.4. Product Overview
  • 7.5. Company Market Share Analysis
  • 7.6. Strategy Mapping, 2023
    • 7.6.1. Bausch Health Companies Inc.
      • 7.6.1.1. Overview
      • 7.6.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.6.1.3. Product Benchmarking
      • 7.6.1.4. Strategic Initiatives
    • 7.6.2. GSK plc.
      • 7.6.2.1. Overview
      • 7.6.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.6.2.3. Product Benchmarking
      • 7.6.2.4. Strategic Initiatives
    • 7.6.3. Abbott
      • 7.6.3.1. Overview
      • 7.6.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.6.3.3. Product Benchmarking
      • 7.6.3.4. Strategic Initiatives
    • 7.6.4. Pfizer, Inc.
      • 7.6.4.1. Overview
      • 7.6.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.6.4.3. Product Benchmarking
      • 7.6.4.4. Strategic Initiatives
    • 7.6.5. Bayer AG
      • 7.6.5.1. Overview
      • 7.6.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.6.5.3. Product Benchmarking
      • 7.6.5.4. Strategic Initiatives
    • 7.6.6. Teva Pharmaceutical Industries Ltd.
      • 7.6.6.1. Overview
      • 7.6.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.6.6.3. Product Benchmarking
      • 7.6.6.4. Strategic Initiatives
    • 7.6.7. Cipla Inc.
      • 7.6.7.1. Overview
      • 7.6.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.6.7.3. Product Benchmarking
      • 7.6.7.4. Strategic Initiatives
    • 7.6.8. Merck & Co., Inc.
      • 7.6.8.1. Overview
      • 7.6.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.6.8.3. Product Benchmarking
      • 7.6.8.4. Strategic Initiatives
    • 7.6.9. Novartis AG
      • 7.6.9.1. Overview
      • 7.6.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.6.9.3. Product Benchmarking
      • 7.6.9.4. Strategic Initiatives
    • 7.6.10. Sun Pharmaceutical Industries Ltd.
      • 7.6.10.1. Overview
      • 7.6.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.6.10.3. Product Benchmarking
      • 7.6.10.4. Strategic Initiatives
    • 7.6.11. Moberg Pharma AB
      • 7.6.11.1. Overview
      • 7.6.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.6.11.3. Product Benchmarking
      • 7.6.11.4. Strategic Initiatives